TaiMed Biologics Inc.

Equities

4147

TW0004147004

Biotechnology & Medical Research

End-of-day quote Taipei Exchange Other stock markets 18:00:00 2024-05-30 EDT			5-day change	1st Jan Change
90.1 ^TWD	+1.69%		+3.33%	+9.88%

05-20	Orient Europharma Co., Ltd. Signs an Exclusive Sales and Marketing Agreement for the New AIDS Drug Trogarzo in Taiwan with Taimed Biologics	CI
05-20	TaiMed Biologics Inc. and Orient EuroPharma Company Limited Signs Trogarzo Commercial License Agreement in Taiwan	CI

TaiMed Biologics Inc. Announces Change of CEO

April 11, 2022 at 03:00 am

TaiMed Biologics Inc. announced change of the Company's CEO. In consideration of his approaching the retirement age, current chairman and CEO James Chang has decided to step down from the CEO post and will be succeeded by Jimmy Chang, Chief Operating Officer of TaiMed. The change has received full approval from the board of directors and will take effect on June 1, 2022.

Latest news about TaiMed Biologics Inc.

Orient Europharma Co., Ltd. Signs an Exclusive Sales and Marketing Agreement for the New AIDS Drug Trogarzo in Taiwan with Taimed Biologics	05-20	CI
TaiMed Biologics Inc. and Orient EuroPharma Company Limited Signs Trogarzo Commercial License Agreement in Taiwan	05-20	CI
TaiMed Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024	05-14	CI
TaiMed Biologics Inc. Announces Enrollment of the Last Patient in Phase 2a Study of the Long-Acting TMB-365/TMB-380 Mabcombination for the Bi-Monthly Maintenance HIV Therapy	05-10	CI
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	03-20	CI
Taimed Biologics and AcedrA Biopharmaceticals Partner to Commercialize Trogarzo in the Middle East and North Africa Region	03-13	CI
Taimed Announces Its Marketing Partner Received Refusal to File Letter for Trogarzo Intramuscular Method of Administration sBLA from the US FDA	02-28	CI
TaiMed Biologics Inc. Receives Patent Approval from the Taiwan Intellectual Property Office for Improving the Pharmacokinetic Performance of TMB-365 Using Histidine Modification Technology	02-21	CI
TaiMed Biologics Inc. Announces US FDA Grants Fast Track Designation to TMB-365/TMB-380 Long-Acting Combination Therapy for HIV Infection	02-06	CI
TaiMed Biologics Inc. Revises the Phase 2 Clinical Study Design of Bi-Monthly Dosing of TMB-365/TMB-380 Combination for the Treatment of HIV Infection	12-21	CI
Taimed Biologics Inc. Announces US FAD Approves the sBLA for the IV Push Administration of the Loading Dose of Trogarzo	12-13	CI
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	11-14	CI
Theratechnologies Reports Results from Trogarzo Intramuscular Administration Study; Tesamorelin Poster Presentation	23-10-13	MT
TaiMed Biologics Inc. Announces Results from Trogarzo Intramuscular (IM) Administration Study	23-10-13	CI
TaiMed Biologics Inc. Completes Data Analysis of the Clinical Trial Sentinel Group for the TMB-365 and TMB-380 Combination as Expected and Confirms the Dosing for Future Execution	23-09-06	CI
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-11	CI
TaiMed Biologics Inc. Completes the Last Patient Visit of the Sentinel Group in the Clinical Study Evaluating Long-Acting TMB-365/TMB-380 Combination Maintenance Therapy	23-06-28	CI
TaiMed Biologics Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-12	CI
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-10	CI
TaiMed Biologics Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-10	CI
TaiMed Biologics Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-10	CI
US FDA Approves the Supplemental Biologicslicense Application for Intravenous (IV) Pushadministration of Trogarzo	22-10-03	CI
TaiMed Biologics Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-14	CI
TaiMed Biologics Inc. Announces First Patient Enrolled in the Study Evaluating Bi-monthly and Quarterly Dosing of the Long-Acting TMB-365/TMB-380 mAb Combination Maintenance Therapy	22-07-28	CI
Tanvex Biopharma and Taimed Biologics Form a Business Alliance to Offer Efficient CDMO Services in Biologics	22-06-14	CI

Chart TaiMed Biologics Inc.

Duration

Period

More charts

Company Profile

TaiMed Biologics Inc. is a Taiwan-based company principally engaged in the research and development of new medicines. The Company mainly provides ibalizumab (TMB-355) and TMB-360, which are applied in the treatment of acquired immune deficiency syndrome (AIDS), and protease inhibitor (TMB-607), which is applied as pro-drugs for AIDS. The Company's ibalizumab is a humanized monoclonal antibody, which can interfere with the penetration of the virus into the cell. Its protease inhibitor uses nanotechnology formulation for subcutaneous and/or intramuscular injections.

Sector

Biotechnology & Medical Research

Calendar

2024-08-08 - Q2 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Ratings for TaiMed Biologics Inc.

Trading Rating

Investor Rating

ESG Refinitiv

C-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

90.1 TWD

Average target price

137 TWD

Spread / Average Target

+52.08%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Bio Therapeutic Drugs

	1st Jan change	Capi.
TAIMED BIOLOGICS INC.	+9.88%	756M
VERTEX PHARMACEUTICALS INCORPORATED	+11.91%	118B
REGENERON PHARMACEUTICALS, INC.	+11.60%	106B
BIONTECH SE	-4.68%	24.28B
ARGENX SE	-0.82%	21.96B
GENMAB A/S	-10.12%	18.16B
WUXI APPTEC CO., LTD.	-42.12%	16.37B
BEIGENE, LTD.	-17.47%	15.56B
NEUROCRINE BIOSCIENCES, INC.	+2.77%	13.63B
SAREPTA THERAPEUTICS, INC.	+34.58%	12.27B

Bio Therapeutic Drugs